Physician profile
James Yee
NPI 1467567388
$6,399.82
in general payments reported to CMS, 2019-2025
19 companies · $464 in 2025
The $464 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,281 · 2020: $245 · 2021: $154 · 2022: $460 · 2023: $332 · 2024: $464 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $4,197.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $537.75 | 2021-2025 | Nucala |
| Alk-Abello, INC | $385.73 | 2019-2023 | Grastek, Odactra |
| Regeneron Healthcare Solutions, INC. | $256.24 | 2019-2024 | Dupixent |
| Genzyme Corporation | $219.42 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $148.01 | 2019-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $127.36 | 2019 | |
| Lilly USA, LLC | $126.79 | 2025 | Zepbound |
| Aerin Medical INC. | $101.78 | 2022-2024 | |
| Stryker Corporation | $59.71 | 2022-2023 | Nasopore |
| Vertex Pharmaceuticals Incorporated | $54.89 | 2025 | |
| Forte Bio-Pharma LLC | $41.01 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.90 | 2025 | Voquezna |
| Fisher & Paykel Healthcare INC | $27.01 | 2023 | Fisher & Paykel Healthcare |
| Kaleo, INC. | $23.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $22.00 | 2019 | |
| Resmed Corp | $18.35 | 2024 | |
| Amgen INC. | $14.23 | 2025 | |
| Greer Laboratories, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.